Format

Send to

Choose Destination
Nat Med. 1995 Aug;1(8):792-7.

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice.

Author information

1
Department of Cancer Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.

Abstract

For Ras oncoproteins to transform mammalian cells, they must be post-translationally modified with a farnesyl group in a reaction catalysed by the enzyme farnesyl-protein transferase (FPTase). Inhibitors of FPTase have therefore been proposed as anti-cancer agents. We show that L-744,832, which mimics the CaaX motif to which the farnesyl group is added, is a potent and selective inhibitor of FPTase. In MMTV-v-Ha-ras mice bearing palpable tumours, daily administration of L-744,832 caused tumour regression. Following cessation of treatment, tumours reappeared, the majority of which regressed upon retreatment. No systemic toxicity was found upon necropsy of L-744,832-treated mice. This first demonstration of anti-FPTase-mediated tumour regression suggests that FPTase inhibitors may be safe and effective anti-tumour agents in some cancers.

Comment in

PMID:
7585182
DOI:
10.1038/nm0895-792
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center